Teva Gets Canadian Rituximab Nod, But Barriers May Remain

 
• By Aidan Fry

Teva has obtained Health Canada clearance for biosimilar rituximab through an alliance with Celltrion. But the Israeli group is keeping quiet on launch plans as patent litigation continues.

Patent_Keyboard
Teva holds approval in Canada for biosimilar rituximab, but patent litigation may yet prove key to market entry • Source: Shutterstock

More from Biosimilars

More from Products